CNJ.TO Cangene Cp
- 169 P/E
- 2.08 P/S
- 1.25 P/B
- -0.15 EPS
- 5.13% Cash ROIC
- 1.47 Cash Ratio
- 0 / 0% Dividend
- 255,197.00 Avg. Vol.
- 66.75M Shares
- 240.3M Market Cap.
Cangene Corporation develops, manufactures, and commercializes therapeutics for infectious diseases or biodefence applications in the United States, Canada, and internationally. The company develops hyperimmunes, which are concentrated specialty antibody preparations made from plasma; and recombinant biopharmaceuticals that are therapeutic proteins made by introducing a particular gene into a host...
Business Wire (press release) - Feb 21, 2014
Washington Post - Dec 11, 2013
Emergent Bio (EBS) to Acquire Cangene Corp in $222M Deal - StreetInsider.com (subscription)
PR Newswire (press release) - May 2, 2011
Winnipeg Free Press - Dec 20, 2013
Canada NewsWire (press release) - Dec 11, 2013
Canada NewsWire (press release) - Feb 13, 2014
Canada NewsWire (press release) - Dec 13, 2013
Canada NewsWire (press release) - Sep 11, 2013
Canada NewsWire (press release) - Feb 20, 2013
Ipsen, Inspiration Biopharmaceuticals sell IB1001 hemophilia B product to Cangene - News-Medical.net
Canada NewsWire (press release) - Jul 29, 2013